Obinutuzumab a Promising Candidate for Plant-Produced Biosimilar

Article

Researchers based in the Republic of Korea have published data suggesting that they were able to produce a promising biosimilar obinutuzumab candidate from the plant Nicotiana benthamiana L. that is equivalent to obinutuzumab produced in glyco-engineered Chinese hamster ovary cells.

Researchers based in the Republic of Korea have published data suggesting that they were able to produce a promising biosimilar obinutuzumab candidate from the plant Nicotiana benthamiana L. that is equivalent to obinutuzumab produced in glyco-engineered Chinese hamster ovary (CHO) cells (CHO-obinutuzumab). Obinutuzumab (Gazyva) is Genentech’s monoclonal antibody treatment for chronic lymphocytic leukemia, which works by depleting CD20-expressing lymphoma cells and B cells.

Obinutuzumab is a so-called “biobetter,” a therapy that has resulted from intentionally altering an existing biologic product in order to improve its clinical effects, require less frequent administration, or enhance tolerability. Obinutuzumab is a biobetter of rituximab (which has a different method of action) has been shown to be less immunogenic and to trigger greater cytotoxicity than rituximab. Obinutuzumab is currently considered the best treatment for non-Hodgkin lymphoma, the authors note.

The cost of producing monoclonal antibodies for anti-cancer immunotherapy is high, and the protein production system in plants has been shown to be a cost-efficient and easy-to-scale-up platform for generating biologic drugs. In addition to being cost-efficient, the use of plants for protein production completely eliminates the risks of virus or residual protein contamination that is associated with mammalian production systems, the researchers note. A more economical and mammalian protein risk-free production platform is in high demand for the entire biopharmaceutical industry, so a plant-based protein-production platform is a promising approach that may contribute to patients’ well-being globally if it results in less-costly drugs.

The study demonstrated that the 2 forms of plant-obinutuzumab generated can be used to kill CD20-expressing lymphoma cells just by direct binding without complements or effector cells, similar to CHO-obinutuzumab.

N. benthamiana is the most widely used experimental host in plant virology, and is susceptible to a wide variety of other plant-pathogenic agents, such as bacteria, making N. benthamiana a cornerstone of host-pathogen research that is also rapidly gaining popularity in studies of protein expression and purification.

The researchers said their study demonstrated that obinutuzumab is a promising candidate as a plant-produced monoclonal antibody because they showed that plant-obinutuzumab has an equivalent ability to bind CD20 and causes direct binding-mediated B-cell death compared to CHO-obinutuzumab.

While there have been no reports of human studies that show plant-derived proteins are more immunogenic than mammalian-derived biotherapeutics, careful observation of the progress toward the use of plant-derived proteins is nevertheless needed for more efficient and rational development of plant-produced bio-drugs.

Related Videos
GBW 2023 webinar
Ryan Haumschild, PharmD, MS, MBA
Ryan Haumschild, PharmD, MS, MBA
andre harvin
Andre Harvin, PharmD
Nabil Saba
Paul Reider
Sonia T. Oskouei, PharmD, BCMAS, DPLA0
Edward Arrowsmith, MD
Chelsee Jensen, PharmD
Related Content
© 2024 MJH Life Sciences

All rights reserved.